Education
About Us
Working with TipRanks
Follow Us
Cullinan Management (CGEM)
NASDAQ:CGEM
CGEM Stock Chart & Stats
$13.13
-$0.28(-2.38%)
At close: 4:00 PM EST
$13.13
-$0.28(-2.38%)
Day’s Range― - ―
52-Week Range$5.68 - $16.74
Previous CloseN/A
Volume73.34K
Average Volume (3M)769.77K
Market Cap
$794.71M
Enterprise Value$686.48M
Total Cash (Recent Filing)$377.90M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 07, 2026EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding60,526,127
10 Day Avg. Volume734,255
30 Day Avg. Volume769,770
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-3.48
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.43K
Enterprise Value/Ebitda-2.84
Forecast
1Y Price Target
$29.69Price Target Upside126.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.06
Revenue Forecast (FY)$25.31M
Bulls Say, Bears Say
Bulls Say
Autoimmune Clinical ReadoutsAnalyst views initial CLN-978 clinical data in rheumatoid arthritis and systemic lupus erythematosus as likely to demonstrate safety, tissue B‑cell depletion, and early signs of activity that could validate the mechanism and attract investor interest.
Intellectual PropertyIssuance of a composition of matter patent for CLN-978 extends intellectual property protection for the asset, reducing competitive risk and supporting long‑term value potential.
Oncology Program PotentialEarly CLN-049 clinical results showing meaningful responses and durable remissions in difficult acute myeloid leukemia subtypes position the program as a potential first‑or‑best‑in‑class asset that could materially increase valuation if durability continues.
Bears Say
Clinical Outcome RiskProgress for multiple programs hinges on dose‑escalation and pivotal readouts, and unfavorable results or insufficient durability at higher doses could materially reduce the company's valuation.
Competition And Timeline RiskExtended multi‑year development timelines combined with investor impatience and competition from other antibodies and cell therapies increase the risk of market share erosion and negative sentiment if competitors report favorable updates sooner.
Financial StrengthNegative return on equity and weak profitability raise valuation concerns until clinical programs translate into clear commercial revenue streams.
Cullinan Management News
CGEM FAQ
What was Cullinan Management’s price range in the past 12 months?
Cullinan Management lowest stock price was $5.68 and its highest was $16.74 in the past 12 months.
What is Cullinan Management’s market cap?
Cullinan Management’s market cap is $794.71M.
When is Cullinan Management’s upcoming earnings report date?
Cullinan Management’s upcoming earnings report date is May 07, 2026 which is in 49 days.
How were Cullinan Management’s earnings last quarter?
Cullinan Management released its earnings results on Mar 10, 2026. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.809 by $0.039.
Is Cullinan Management overvalued?
According to Wall Street analysts Cullinan Management’s price is currently Undervalued.
Does Cullinan Management pay dividends?
Cullinan Management does not currently pay dividends.
What is Cullinan Management’s EPS estimate?
Cullinan Management’s EPS estimate is -0.83.
How many shares outstanding does Cullinan Management have?
Cullinan Management has 60,526,127 shares outstanding.
What happened to Cullinan Management’s price movement after its last earnings report?
Cullinan Management reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.809. Following the earnings report the stock price went down -2.613%.
Which hedge fund is a major shareholder of Cullinan Management?
Currently, no hedge funds are holding shares in CGEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cullinan Management Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.69 (126.12% Upside)
$29.69 (126.12% Upside)
Blogger Sentiment
Bullish
CGEM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $945.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 15.5%
Last 30 Days ▲ 15.5%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
48.83%
12-Months-Change
Fundamentals
Return on Equity
-46.19%
Trailing 12-Months
Asset Growth
-27.84%
Trailing 12-Months
Company Description
Cullinan Management
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CGEM Stock 12 Month Forecast
Average Price Target
$29.69
▲(126.12% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---